[A case of acute cholestatic hepatitis associated with Orlistat].
Orlistat(Xenical(R), Roche) is considered a safe and effective drug to treat obesity by reduced absorption of 30% digested fat. To date, no serious adverse effects affecting the liver have been published except a case of subacute hepatic failure leading to liver transplantation in a young women with moderate obesity treated with orlistat. We report a case of acute cholestatic hepatitis in a young woman with moderate obesity treated with orlistat: a 33-year-old female admitted for the evaluation of jaundice. Abdominal ultrasonography, ERCP, routine chemistry, viral markers, and a fine needle biopsy of liver were performed. Microscopic findings of the liver biopsy specimen were compatible with acute cholestatic hepatitis. After steroid therapy, liver function was improved.
Kim
Doh Hyun
DH
Department of Gastroenterology, Ajou University College of Medicine, Suwon, Korea.
Lee
Eun Hee
EH
Hwang
Jae Chul
JC
Jeung
Jai Hak
JH
Kim
Do Hyun
DY
Cheong
Jae Youn
JY
Cho
Sung Won
SW
Kim
Young Bae
YB
D000208:Acute Disease; D000328:Adult; D019440:Anti-Obesity Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis* / Q000209:etiology; D002779:Cholestasis / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D008049:Lipase / Q000037:antagonists & inhibitors; D000077403:Orlistat
D019440:Anti-Obesity Agents; D007783:Lactones; D000077403:Orlistat; D008049:Lipase